search
Back to results

Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Tranexamic Acid (TXA)
ε-Aminocaproic Acid (EACA)
Sponsored by
Miller Orthopedic Specialists
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Tranexamic acid, 6-Aminocaproic Acid, Arthroplasty, Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Antifibrinolytic Agents, Fibrin Modulating Agents, Pharmacologic Actions, Coagulants, Therapeutic Uses

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Persons aged 18 - 90 years who are scheduled to undergo a unilateral total knee replacement surgery

Exclusion Criteria:

  • Non-English speaking individuals
  • Individuals with a history of deep vein thrombosis or pulmonary embolism within one year
  • Individuals with a history of coagulopathy
  • Heart stent within one year
  • Pre-operative autologous blood donation
  • Unwilling or unable to take Coumadin for deep vein thrombosis (DVT) prophylaxis
  • Received nonsteroidal anti-inflammatory drug (NSAID) or platelet antiaggregant treatment within five days prior to surgery
  • Pre-operative creatinine greater than 1.5mg/dL

Sites / Locations

  • Miller Orthopedic Specialists

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Tranexamic acid (TXA)

ε-Aminocaproic Acid (EACA)

Arm Description

1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.

7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.

Outcomes

Primary Outcome Measures

Transfusion rate

Secondary Outcome Measures

Full Information

First Posted
June 6, 2013
Last Updated
March 18, 2016
Sponsor
Miller Orthopedic Specialists
Collaborators
CHI Health Mercy Hospital, Creighton University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01873768
Brief Title
Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement
Official Title
A Randomized Controlled Trial of Tranexamic Acid and ε-Aminocaproic Acid to Reduce Blood Loss Following Total Knee Arthroplasty
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Miller Orthopedic Specialists
Collaborators
CHI Health Mercy Hospital, Creighton University Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic acid (TXA), research on the clinical impact of ε-aminocaproic acid (EACA) in total knee arthroplasty (TKA) is limited. The primary aim of this study is to determine whether TXA and EACA provide similar blood decreasing effects following TKA or whether one drug provides a superior effect over the other in reducing patients' blood loss.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Tranexamic acid, 6-Aminocaproic Acid, Arthroplasty, Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Antifibrinolytic Agents, Fibrin Modulating Agents, Pharmacologic Actions, Coagulants, Therapeutic Uses

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
194 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tranexamic acid (TXA)
Arm Type
Active Comparator
Arm Description
1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.
Arm Title
ε-Aminocaproic Acid (EACA)
Arm Type
Active Comparator
Arm Description
7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.
Intervention Type
Drug
Intervention Name(s)
Tranexamic Acid (TXA)
Other Intervention Name(s)
Cyklokapron
Intervention Description
1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
Intervention Type
Drug
Intervention Name(s)
ε-Aminocaproic Acid (EACA)
Other Intervention Name(s)
Amicar
Intervention Description
7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
Primary Outcome Measure Information:
Title
Transfusion rate
Time Frame
1.5 to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Persons aged 18 - 90 years who are scheduled to undergo a unilateral total knee replacement surgery Exclusion Criteria: Non-English speaking individuals Individuals with a history of deep vein thrombosis or pulmonary embolism within one year Individuals with a history of coagulopathy Heart stent within one year Pre-operative autologous blood donation Unwilling or unable to take Coumadin for deep vein thrombosis (DVT) prophylaxis Received nonsteroidal anti-inflammatory drug (NSAID) or platelet antiaggregant treatment within five days prior to surgery Pre-operative creatinine greater than 1.5mg/dL
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clifford K Boese, MD
Organizational Affiliation
Miller Orthopedic Specialists
Official's Role
Principal Investigator
Facility Information:
Facility Name
Miller Orthopedic Specialists
City
Council Bluffs
State/Province
Iowa
ZIP/Postal Code
51503
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

We'll reach out to this number within 24 hrs